Abbott posted a 13% increase in reported sales and 4.8% comparable sales growth for Q2 2026, with GAAP diluted EPS at $0.53 and adjusted EPS at $1.31. The company reaffirmed its full-year 2026 sales growth guidance of 6.5% to 7.5% and raised its adjusted EPS guidance to $5.45-$5.60. Abbott also returned $2.1 billion to shareholders through dividends and share buybacks. Key business segments like Diagnostics and Medical Devices showed strong growth, supported by new product launches and acquisitions, signaling continued momentum for the rest of the year.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
